about
Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strainsA novel polyamide SL-A92 as a potential fungal resistance blocker: synthesis and bioactivities in Candida albicans.Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection.Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeastsIdentification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.Glycosylation status of the C. albicans cell wall affects the efficiency of neutrophil phagocytosis and killing but not cytokine signaling.Distribution of yeast-like fungi at a university hospital in TurkeyEarly neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus Conidia.Novel approaches to antifungal prophylaxis.Hedgehog zoonoses.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsAn outbreak of Pichia ohmeri infection in the paediatric intensive care unit: case reports and review of the literature.Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicansContribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults.Optimizing efficacy of Amphotericin B through nanomodification.Altered dynamics of Candida albicans phagocytosis by macrophages and PMNs when both phagocyte subsets are presentCandida albicans-macrophage interactions: genomic and proteomic insights.New and investigational triazole agents for the treatment of invasive fungal infections.Antifungal Activity of the Ethanol Extract from Flos Rosae Chinensis with Activity against Fluconazole-Resistant Clinical CandidaInvasive aspergillosis: resistance to antifungal drugs.Th17 cells in immunity to Candida albicans.Novel insights into host-fungal pathogen interactions derived from live-cell imaging.Invasive Primary Colonic Aspergillosis in the Immunocompetent Host without Classical Risk Factors.The Goldilocks model of immune symbiosis with Mycobacteria and Candida colonizers.Integrated proteomics and genomics strategies bring new insight into Candida albicans response upon macrophage interaction.Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans.The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases.Invasive fungal infections in pediatric hematopoietic stem cell transplant patients.A Protective Mechanism in Lungs of Rats Experimentally Infected with Aspergillus fumigatusSystematic internal transcribed spacer sequence analysis for identification of clinical mold isolates in diagnostic mycology: a 5-year study.A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans.Fungal infections in immunocompromised patients.Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans.
P2860
Q24623710-59A33C64-A5C6-4563-92BC-6F306D69EBADQ33557539-D9B38A1A-180F-47C4-B9F5-391BF920C5B5Q33858728-9CB36268-AAB2-4A24-8D80-E4BBA65E8F4BQ34315473-35A9258F-DB75-405B-A7BD-41A68ABE1BECQ34459120-92349D95-2A60-4E2F-87F4-24D0980700D0Q35059329-2AAABE0D-24A2-42F7-BB77-76BD3E71A73DQ35105024-A5F894A4-6CA3-4D91-BC97-4A418CA36E3EQ35220405-1C278AFE-2699-4FF2-B9B3-31747CF2B4EFQ35790799-8ABF5511-8E0F-4360-A701-5C012212BB17Q35804309-9B7B9A25-38B1-4F3C-9D70-8F9AA4046EDFQ36087577-29ED8772-4993-4A7D-A709-24C9C9522C2CQ36176375-2BAF2648-BF6F-428A-A911-8F97ECE08781Q36267368-0BF4BA2D-6524-4D37-BFCA-09E88A0B09D8Q36892250-D45E990F-3F29-43AC-9A39-891FBFEA0051Q37178176-D08D34D0-6253-4480-980B-AD3BBE3DC776Q37258670-0A90F5A9-96E4-46BF-B8E2-EB43931CC6FAQ37345802-56019D9B-F279-4353-A07E-AE345BFBB8F8Q37364295-0AD36254-EAA0-4AC2-857A-0C5AE2D04DC7Q37682167-F026FB15-F77C-4F1E-85EC-5D6DF28D113FQ37983464-871FCDAB-D49D-4F36-8F6F-56801401F305Q38011298-AA07487A-E8D4-41F3-9B60-BF0BEA898D66Q38268265-A475A6C1-5D0C-4854-AD39-6D6C3B6AA2E3Q38563506-F7D49E6E-2D45-429B-AD2F-090C4DF12537Q39344161-3E65C22C-00B3-49D2-9B6D-4F33A7BC27A9Q40197295-E46BF384-073B-4726-8465-F2ED9A6BF4C6Q40309090-A311973B-F963-44B1-87D1-9EBBCB4946B4Q40335405-FC523179-9FB4-4E8E-A15D-2502D59637CCQ40424937-A45752BB-75CC-4EAE-9049-5C665C6C55F4Q41480974-B28F7D01-B634-4894-8515-0644D348BDB4Q42217710-E52484D5-20EB-4ABD-8FE2-4C30AF3BD704Q42575238-54F6D77B-EDF8-4D51-A7A2-1BE230DEE091Q43742898-01321BB0-41D4-4D48-A3C0-4E5EB632F8CDQ43993301-8D041742-3C99-48C5-BD37-06831B0708AEQ44620717-29336DF2-9B36-4214-BC48-B873D4C92A4DQ54181112-A0DB9761-0A0A-415E-80C3-A13F3A193777
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Assessing risk factors for systemic fungal infections.
@ast
Assessing risk factors for systemic fungal infections.
@en
Assessing risk factors for systemic fungal infections.
@nl
type
label
Assessing risk factors for systemic fungal infections.
@ast
Assessing risk factors for systemic fungal infections.
@en
Assessing risk factors for systemic fungal infections.
@nl
prefLabel
Assessing risk factors for systemic fungal infections.
@ast
Assessing risk factors for systemic fungal infections.
@en
Assessing risk factors for systemic fungal infections.
@nl
P2093
P2860
P1476
Assessing risk factors for systemic fungal infections.
@en
P2093
P2860
P356
10.1046/J.1365-2354.2001.00241.X
P407
P577
2001-03-01T00:00:00Z